Skip to content

study of water soluble extract of Shalaparni and Bhringaraja for the treatment of Essential Hypertension â??

â??Clinical efficacy of aqueous extract of Shalaparni (Desmodium gangeticum) and Bhringaraja (Eclipta alba) in the management of Essential Hypertension (Vyanabala Vaishamya)â??

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/12/010843
Enrollment
45
Registered
2017-12-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diagnosed stage-2 Essential Hypertension having no known complications of disease

Interventions

Intervention1: Shalaparni (Desmodium gangeticum): aqueous extract of Shalaparni (Desmodium gangeticum) Capsule500 mg BD for 1 month. Intervention2: Bhringaraja (Eclipta alba): aqueous extract of Bhrin

Sponsors

National institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients willing to sign the consent form for the clinical trials. ii. Patients belonging to either sex between the age group 30 years to 60years. iii. Patients who are already diagnosed as Essential hypertension (EHT) will be selected. iv. Patients having systolic blood pressure (SBP) up to 160 and diastolic blood pressure (DBP) up to 100 will be selected for the study and in any type of emergency condition patient will be treated in emergency.

Exclusion criteria

Exclusion criteria: i. Patient below the age of 30 years and above 60 years. ii. Patient having systemic / serious complication of Cardiovascular / Cerebrovascular / Renal system. iii. Hypertensive retinopathy iv. Malignancy v. History of liver diseases in the recent past (If the duration of the diseases is more than 5 years.) vi. Pregnancy induced hypertension.

Design outcomes

Primary

MeasureTime frame
reduction in systolic and diastolic blood pressureTimepoint: 1 month

Secondary

MeasureTime frame
1) Reduction in renal and cerebrovascular complications, 2) Decrease in cardiac riskTimepoint: 1 month

Countries

India

Contacts

Public ContactDr Shalinee

National Institute of Ayurveda

joshirk1964@gmail.com9414322297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026